Unitedhealth Group Inc (UNH) concluded trading on Wednesday at a closing price of $524.52, with 4.06 million shares of worth about $2.13 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.71% during that period and on January 08, 2025 the price saw a gain of about 2.00%. Currently the company’s common shares owned by public are about 923.00M shares, out of which, 918.18M shares are available for trading.
Stock saw a price change of 3.69% in past 5 days and over the past one month there was a price change of -4.57%. Year-to-date (YTD), UNH shares are showing a performance of 3.69% which decreased to -2.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $436.38 but also hit the highest price of $630.73 during that period. The average intraday trading volume for Unitedhealth Group Inc shares is 4.55 million. The stock is currently trading 2.59% above its 20-day simple moving average (SMA20), while that difference is down -6.07% for SMA50 and it goes to -2.85% lower than SMA200.
Unitedhealth Group Inc (NYSE: UNH) currently have 923.00M outstanding shares and institutions hold larger chunk of about 89.60% of that.
The stock has a current market capitalization of $482.71B and its 3Y-monthly beta is at 0.62. PE ratio of stock for trailing 12 months is 34.07, while it has posted earnings per share of $15.39 in the same period. Its PEG reads 2.62 while making debt-to-equity ratio of 0.83. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for UNH, volatility over the week remained 2.11% while standing at 2.70% over the month.
Stock’s fiscal year EPS is expected to rise by 9.92% while it is estimated to increase by 8.10% in next year. EPS is likely to shrink at an annualized rate of 13.00% for next 5-years, compared to annual growth of 14.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on January 06, 2025 offering a Buy rating for the stock and assigned a target price range of between $625 and $610 to it. On October 11, 2024, KeyBanc Capital Markets Initiated their recommendations, while on July 17, 2024, Jefferies Upgrade their ratings for the stock with a price target of $647. Stock get an Outperform rating from RBC Capital Mkts on July 17, 2024.
